Matt Phipps
Stock Analyst at William Blair
(0.08)
# 4,132
Out of 4,784 analysts
16
Total ratings
16.67%
Success rate
-43.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMAB Genmab | Upgrades: Outperform | n/a | $19.90 | - | 2 | Mar 11, 2025 | |
| KROS Keros Therapeutics | Downgrades: Market Perform | n/a | $10.79 | - | 1 | Dec 12, 2024 | |
| UPB Upstream Bio | Initiates: Outperform | n/a | $6.87 | - | 1 | Nov 5, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | n/a | $6.49 | - | 1 | Sep 30, 2024 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $8.02 | - | 1 | Apr 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Market Perform | n/a | $60.02 | - | 1 | Oct 27, 2023 | |
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $4.92 | - | 2 | Mar 16, 2023 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $29.10 | - | 1 | Nov 14, 2022 | |
| INKT MiNK Therapeutics | Initiates: Outperform | n/a | $9.03 | - | 1 | Nov 9, 2021 | |
| TPST Tempest Therapeutics | Initiates: Outperform | n/a | $0.77 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.46 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $138.37 | - | 2 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $44.61 | - | 1 | Apr 8, 2021 |
Genmab
Mar 11, 2025
Upgrades: Outperform
Price Target: n/a
Current: $19.90
Upside: -
Keros Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $10.79
Upside: -
Upstream Bio
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $6.87
Upside: -
Tenax Therapeutics
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $6.49
Upside: -
Cullinan Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $8.02
Upside: -
Bristol-Myers Squibb Company
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $60.02
Upside: -
Kezar Life Sciences
Mar 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $4.92
Upside: -
Janux Therapeutics
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $29.10
Upside: -
MiNK Therapeutics
Nov 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $9.03
Upside: -
Tempest Therapeutics
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.77
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $4.46
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $138.37
Upside: -
Apr 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $44.61
Upside: -